Astex in the News
2O26
Astex is proud to announce that Dr David Rees, former Chief Scientific Officer of Astex and Chair of our Scientific Advisory Board, was appointed a Commander of the Order of the British Empire (CBE) in the King’s Birthday honours list for services to Chemistry and Innovation. David was recently also made a Fellow of the Royal Society (FRS). These recent achievements are testament to a distinguished career in drug discovery, his contributions to Astex’ success as well as the discovery of Sugammadex whilst he was at MSD/Organon.
June 15, 2026 – read news
Dr David Rees FMedSci FRS, formerly Chief Scientific Officer at Astex Pharmaceuticals and the current Chair of Astex’s Scientific Advisory Board, is one of the exceptional scientists elected as a Fellow of the Royal Society
May 27, 2026 – read news
Charlotte Cane MP visits Cambridge Science Park to meet innovative life sciences companies
March 31, 2026 – read news
2O25
Astex Announces New Senior Management Team Appointments
October 06, 2025 – read news
BMS, Takeda and Astex join AI training consortium
October 02, 2025, PMLiVE – read news
BMS and Takeda dive into AI data pool, joining peers in collaborative push to unfold the future
October 01, 2025, Fierce Biotech – read news
AISB Network Expands Federated OpenFold3 Initiative with Three New Pharma Contributors
October 01, 2025, Apheris website – read news
Is this the U.K.’s moment for biotech?
September 23, 2025, BioCentury website – Listen to Michelle Jones, Astex on BioCentury podcast
UK to become world leader in drug discovery as Technology Secretary heads for London Tech Week
June 09, 2025, gov.uk – read news
Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial
May 30, 2025, finance.yahoo.com – read news
Mosaic adds to cancer combo pattern by licensing 2 clinical-stage drugs from Astex
April 24, 2025, Fierce Biotech – read news
Mosaic Therapeutics in-licenses two clinical-stage oncology programs from Astex Pharmaceuticals for development as proprietary combination therapies
April 24, 2025, Mosaic Therapeutics website – read news
J&J broadens its bladder cancer push
April 16, 2025, ApexOnco website – read news
First treatment for common bladder cancer recommended by NICE
April 15, 2025, Cancer Research Horizons website – read news
ICR welcomes NICE recommendation of capivasertib for advanced breast cancer
April 11, 2025, ICR website – read news
Breakthrough breast cancer drug approved for the NHS
April 11, 2025, The Times – read news (behind paywall)
Solid gold future as Astex pursues further growth in wake of silver jubilee
Feb 4, 2025, Business Weekly – read news
Oxbridge growth minister keen to ‘get things done’
January 31, 2025, BBC News website – read more
Science Minister visits Cambridge company on visit to revive Oxford-Cambridge Arc
January 30, 2025, Cambridge Independent – read more
Minister Vallance underlines how Oxford-Cambridge corridor ambitions can boost whole UK
January 30, 2025 – read more
2O24
Harren Jhoti, Astex Pharmaceuticals President and CEO jointly wins Executive of the Year Award (Commercial-Stage Companies) at Scrip Awards
Dec 2024, Scrip Awards website – read more
Jeremy Carmichael (SVP of Corporate Development & Head of Business Development at Astex) accepted the award on Harren’s behalf.
Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence
Nov 2024, Novartis website – read more
Astex wins the Research and Development Achievement Award at the Pharma Awards
Sept 2024, Pharma Industry Awards UK website – read more
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Sept 2024, Novartis website – read more
OpenFold AI Research Consortium Welcomes Six New Members: Astex, Biogen, Congruence, Polaris Quantum, Psivant, and SandboxAQ
August 2024, Business Wire press release – read more
AI and Drug Discovery with Harren Jhoti
July 2024, Bloomberg podcast – listen
First AKT-targeting drug capivasertib to hit the market, could it open the door for more?
July 2024, Labiotech – read more
MHRA approves first-in-class breast cancer drug
July 2024, ICR website – read more
Jessie Stow, Astex Pharmaceuticals apprentice, wins prestigious Royal Society of Chemistry Prize
June 2024, RSC website – read more
Harren Jhoti discusses Astex’s discovery and preclinical work that has contributed to three approved medicines
May 2024 – watch video
Cambridge A-listers Astex and AstraZeneca toast progress of another cancer drug prospect
January, Business Weekly (page 23) – read more
2O23
Interview with Harren Jhoti: How Astex built a business based on fragment-based drug discovery
Nov – Dec, MedNous – Issue 2023 – read more
Third Success from Astex Drug Discovery Pharma Collaborations as AstraZeneca Receives US Marketing Approval for Cancer Drug Truqap (capivasertib).
November 17, 2023 – read more
Dr Harren Jhoti FRS OBE wins Business Person of the Year at the 21st annual Asian Achievers Awards
September 15, 2023 – read more
Astex bags another cancer deal with MSD, this time for “undruggable” p53 target
August 9, 2023 – read more
UK’s Astex adds onto Merck partnership via $35M upfront for tumor suppressor protein candidates
August 8, 2023 – read more
Merck enlists Astex to search for p53 cancer drug in expanded deal
August 8, 2023 – read more
Astex hails trials success of superdrug that saves lives and cuts recurrence risk for thousands of breast cancer patients
June 7, 2023 – read more
Breast cancer drug cuts risk of most common form returning by 25%
June 2, 2023 – read more
Astex wins Life Science Company of the Year at the Cambridge Independent Science and Technology Awards 2023
May 18, 2023 – read more
Astex is a finalist for the Cambridge Independent Science and Technology Awards 2023
March 15, 2023 – read more
Astex and Cardiff University Medicines Discovery Institute to Collaborate on neurodegenerative diseases
February 14, 2023 – read more
Cardiff University and Astex in drug discovery collaboration
February 13, 2023 – read more
Astex and Cardiff University seek new drugs to treat neurodegenerative diseases
February 13, 2023 – read more
Fit for a king! Astex chief made OBE in historic honours list
January 3, 2023 – read more
Astex Co-founder and CEO Harren Jhoti Awarded OBE in the King’s New Year Honours
January 1, 2023 – read more
2O22
Astex and AstraZeneca deliver ‘landmark’ breast cancer drug
December 15, 2022 – read more
Cambridge on the cusp of its third blockbuster drug coup
December 13, 2022 – read more
New targeted drug shows benefit against breast cancer in first phase III trial
December 9, 2022 – read more
New targeted drug shows benefit against breast cancer in first phase III trial
December 8, 2022 – read more
Cryo-EM Incites a “Resolution Revolution,” Rousing Drug Discovery article – Includes interview with Astex’s Senior Director (Molecular Sciences) Dr. Pamela Williams featured in the Cryo-EM meets fragment-based drug design section
December 7, 2022 – read more
Cancer Research UK and Newcastle University announce alliance extension with Astex Pharmaceuticals (UK)
November 22, 2022 – read more
Capivasertib plus Faslodex significantly improved progression-free survival vs. Faslodex in CAPItello-291 Phase III trial in advanced HR-positive breast cancer
October 26, 2022 – read more
Astex wins 3 awards for participating in The BioIndustry Association (BIA) 850 Global Challenge for Kidney Research UK 2022
May 30, 2022 – read more
Astex enters new partnership with the UK Dementia Research Institute to accelerate progress in dementia research
April 6, 2022 – read more
2O21
David Rees, Chief Scientific Officer, joins The Rosalind Franklin Institute (RFI) Board of Directors
September 1, 2021 – read more
Astex scientist, Pamela Williams, wins the Biochemical Society’s Industry and Academic Collaboration Award
September, 2021 – read more
Taiho and Astex Extend Strategic Oncology Collaboration with MSD Granting Exclusive License to SHP2 Program
January 13, 2021 – read more
2O2O
David Rees, Chief Scientific Officer, inducted to the Royal Society of Chemistry BMCS (Biological and Medicinal Chemistry Sector) Hall of Fame
December 1, 2020 – read more
Astex’s VP Intellectual Property, Michelle Jones, is named as one of the Managing IP Corporate IP Stars of 2020
July 28, 2020 – read more
Astex CSO, David Rees, elected as new Fellow of the Academy of Medical Sciences
May 13, 2020 – read more
Merck Establishes Strategic Oncology Collaboration with Taiho and Astex (KRAS programme)
January 6, 2020 – read more
2O19
An Entrepreneurs Journey Part II: Harren Jhoti, President and CEO Astex Pharmaceuticals
Nov 25, 2019 – Read more
An Entrepreneurs Journey Part I: Harren Jhoti, President and CEO Astex Pharmaceuticals text
Nov 22, 2019 – Read more
Astex is featured in Biology Impacting Lives, an ITN Productions programme created in partnership with the Royal Society of Biology
April 15, 2019 – view video
https://astx.com/wp-admin/post.php?post=1618&action=edit&classic-editor=1#save
2O15
Open Innovation: The Answer To Slow Pharmaceutical Productivity
September 1, 2015 – read more
© Astex Pharmaceuticals
All rights reserved
